ArticleFrontiers in cell and developmental biology2026
Conditional deletion of
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Bone remodeling depends on coordinated signaling between bone-resorbing osteoclasts and bone-forming osteoblasts through locally secreted coupling factors. Disruption of this balance leads to decreased bone mass, resulting in conditions such as osteoporosis. Osteoclast-derived anabolic factors, or clastokines, have emerged as attractive therapeutic candidates with the potential of selectively enhancing bone formation without suppressing resorption. Osteoblast-derived WNT5A is an established coupling factor promoting osteoclastogenesis; however, osteoclast-derived WNT5A specific contribution to bone homeostasis and the downstream mechanism by which it acts on osteoblasts remains undefined. Methods: This study aimed to address this gap using a myeloid-specific conditional knockout mouse that selectively targets osteoclast-derived WNT5A while leaving osteoblast-derived WNT5A intact. Wnt5a was conditionally deleted in osteoclast precursors and their progeny using LysM-Cre; Wnt5aF/F mice and both male and female knockout mice were characterized by μCT, histomorphometry, serum bone turnover markers, transcriptomic profiling of osteoblast-enriched cells, and in vitro focal adhesion and migration assays. Results: Both male and female knockout mice displayed significantly reduced trabecular volume compared with controls. This low bone mass phenotype was driven by decreased osteoblast number and activity, with no significant changes in osteoclast number or resorptive function. Transcriptomic profiling of osteoblast-enriched cells revealed dysregulation of genes involved in focal adhesion, integrin binding, and cell communication, alongside upregulation of stress-related gene networks. Histological and functional analyses demonstrated that loss of osteoclast-derived WNT5A impaired extracellular matrix maturation and disrupted osteoblast focal adhesion assembly and migration. Discussion: Together, our study establishes osteoclast-derived WNT5A as a clastokine that promotes bone formation in vivo by regulating osteoblast migration and adhesion dynamics. These findings establish a mechanistic link between osteoclast secretory activity and osteoblast function and highlight the context-dependent and cell-of-origin specific roles of WNT5A in skeletal homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.